ЕRYTHEMATOTELANGIECTATIC ROSACEA: THE OPTIMIZATION OF DIAGNOSTICS AND THERAPY

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Presents the modern classification, definition and differential diagnostic criteria of the clinical picture of rosacea. The social significance of dermatosis, the importance and the ability to eliminate the symptoms of the disease in the early stages, achieve a sustainable clinical effect to the ”Clear“ skin condition. The article presents the first domestic positive experience in the complex treatment of the erythematotelangiectatic rosacea, using broadband pulsed light radiation using a 0.5% brimonidine tartrate gel (Mirvazo Derm®). The effectiveness of the method is estimated using a multispectral analysis of the skin, which allows real-time to see the morphological structure of the pathological process, as well as create a map of the distribution of hemoglobin and measure its concentration in the lesions. During research there were 60 patients aged 26 to 55 years with an established diagnosis of erythematotelangiectatic rosacea. The duration of the disease ranged from 6 months to 12 years. We have demonstrated the high efficiency and tolerability of the combined method, the absence of side and undesirable effects in patients with rosacea with an erythematotelangiectatic subtype.

Full Text

Restricted Access

About the authors

Tatiana S. Rusina

I.M. Sechenov First Moscow State Medical University (Sechenov’s University); Central Institute of Dermatocosmetology

Email: rusina@cidk.ru
Moscow, 119991, Russian federation; Moscow, 119034, Russian Federation
Department of Dermatology and Venereal Diseases

E. S Snarskaya

I.M. Sechenov First Moscow State Medical University (Sechenov’s University)

Moscow, 119991, Russian federation
Department of Dermatology and Venereal Diseases

References

  1. Kellen R., Silverberg N.B. Pediatric rosacea. Cutis. 2016; 98(1): 49-53.
  2. Weinkle A.P., Doktor V., Emer J. Update on the management of rosacea. Plast. Surg. Nurs. 2015; 35(4): 184-202.
  3. Манн М.В., Берк Д.Р., Попкин Д.Л., Бейлисс С.Д. Справочник дерматолога. Практическое руководство. М.: Изд. Панфилова; БИНОМ; 2013.
  4. Kyriakis K.P., Palamaras I., Terzoudi S., Emmanuelides S., Michailides C., Pagana G. Epidemiologic aspects of rosacea. J. Am. Acad. Dermatol. 2005; 53(5): 918-9.
  5. Олисова О.Ю., Кочергин Н.Г., Смирнова Е.А. Инновации в наружной терапии rosacea. Российский журнал кожных и венерических болезней. 2017; 20(5): 270-4.
  6. Wilkin J., Dahl M., Detmar M., Drake L., Feinstein A., Odom R., Powell F. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am. Acad. Dermatol. 2002; 46(4): 584-7.
  7. Elewski B.E., Draelos Z., Dreno B., Jansen T., Layton A., Picardo M. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J. Eur. Acad. Dermatol. Venereol. 2011; 25(2): 188-200.
  8. Хайрутдинов В.Р. Розацеа: современные представления о патогенезе, клинической картине и лечении. Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2014; 19(2): 32-7.
  9. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J. Am. Acad. Dermatol. 2013; 69(6, Suppl. 1): S15-26.
  10. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 2007; 13(8): 975-80.
  11. Yamasaki K., Gallo R.L. Rosacea as a disease of cathelicidins and skin innate immunity. J. Investig. Dermatol. Symp. Proc. 2011; 15(1): 12-5.
  12. Wilkin J.K. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J. Invest. Derm. 1981; 76(1): 15-8.
  13. West J.B., Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet. 1992; 340(8822): 762-7.
  14. Rice W.G., Weiss S.J. Regulation of proteolysis at the neutrophilsubstrate interface by secretory leukoprotease inhibitor. Science. 1990; 249(4965): 178-81.
  15. Motley R.J., Barton S., Marks R. The signifi cance of telangiectasia in rosacea. In: Marks R., Plewig G., eds. Acne and Related Disorders: An International Symposium. London: Informa; 1989: 339-44.
  16. Dirschka T., Tronnier H., Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br. J. Dermatol. 2004; 150(6): 1136-41.
  17. Lacey N., Delaney S., Kavanagh K., Powell F.C. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br. J. Dermatol. 2007; 157(3): 474-81.
  18. Бутов Ю.С., Скрипкин Ю.К., Иванов О.Л., ред. Дерматовенерология. М.: ГЭОТАР-Медиа; 2013.
  19. Kassir R., Kolluru A., Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias. J. Cosmet. Laser Ther. 2011; 13(5): 216-22.
  20. Аравийская Е.Р., Соколовский Е.В., ред. Руководство по дерматокосметологии. CПб.: Фолиант; 2008.
  21. Micali G., Gerber P.A., Lacarrubba F., Schäfer G. Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features. J. Clin. Aesthet. Dermatol. 2016; 9(7): 30-9.
  22. Mansouri Y., Goldenberg G. Devices and topical agents for rosacea management. Cutis. 2014; 94(1): 21-5.

Statistics

Views

Abstract - 41

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2019 Rusina T.S., Snarskaya E.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies